Special Issue

Novel Insights into Interstitial Lung Disease Diagnostics and Treatment

Message from the Guest Editors

In recent years, interstitial lung diseases (ILD) have presented an amazing development. The different international consensus have made it possible to clarify the different types of ILDs and optimal therapies, especially for idiopathic pulmonary fibrosis (IPF). Recent clinical trials have permitted the use of nintedanib and pirfenidone to reduce the progression of fibrotic disease. Additionally, the development of new techniques and the multidisciplinary discussion have been definitive in the progress of diagnosis accuracy. However, many areas are currently in development. The development of the "fibrotic pulmonary phenotype" definition in recent years and the beneficial effects of antifibrotics in this group has been one of the main recent advances in the field. This recent research has brought the ILD field into a novel and exciting moment. This Special Issue of *Journal of Respiration* aims to bring together current research and opinions on new concepts in diagnosis and treatment of interstitial lung diseases.

Guest Editors

Dr. Jacobo Sellarés Interstitial Lung Disease Unit, Respiratory Department, Hospital Clinic de Barcelona (Barcelona), 08036 Barcelona, Spain

Dr. Fernanda Hernandez

Department of Respiratory Medicine, Respiratory Institute, Hospital Clinic Barcelona, 08036 Barcelona, Spain

Deadline for manuscript submissions

closed (31 December 2021)



Journal of Respiration

an Open Access Journal by MDPI



mdpi.com/si/67196

Journal of Respiration Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jor@mdpi.com

mdpi.com/journal/

jor





Journal of Respiration

an Open Access Journal by MDPI



jor



About the Journal

Message from the Editor-in-Chief

Over the last decade, the amount of information pertaining to thoracic structures has been unprecedented. The thorax is unique in terms of the different structures that involve the respiratory systemlungs, pleura, upper and lower respiratory tract-all located in the mediastinum that by itself represents a different compartment with its own wealth of conditions, and that also includes the Thymic gland. Therefore, we believe that the availability of a new open access journal, JoR, dedicated to highlighting and disseminating information related to the respiratory system is not only timely but is also absolutely necessary. As we can see, the information related to the respiratory systems is vast and there could not be anything more and better than to have a journal that is dedicated to the promotion, dissemination, and efficient publication of timely articles on the respiratory system including all its structures.

Editor-in-Chief

Prof. Dr. Cesar A. Moran Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 30.5 days after submission; acceptance to publication is undertaken in 5.6 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names published annually in the journal.